CRISPR Therapeutics AG $CRSP Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 20.8% in the second quarter, Holdings Channel.com reports. The fund owned 50,185 shares of the company’s stock after buying an additional 8,645 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CRISPR Therapeutics were worth $2,441,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SVB Wealth LLC acquired a new stake in CRISPR Therapeutics in the first quarter valued at $25,000. Costello Asset Management INC acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth $27,000. IFP Advisors Inc raised its stake in shares of CRISPR Therapeutics by 24.6% during the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after buying an additional 181 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock worth $45,000 after buying an additional 978 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of CRISPR Therapeutics by 1,923.1% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,841 shares of the company’s stock worth $90,000 after buying an additional 1,750 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 2.4%

Shares of CRSP stock opened at $64.17 on Wednesday. The company has a market capitalization of $5.84 billion, a price-to-earnings ratio of -11.82 and a beta of 1.84. The firm has a 50-day moving average price of $61.98 and a 200 day moving average price of $51.95. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.18. The company had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The firm’s revenue was up 72.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.49) EPS. As a group, research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several research reports. Barclays lifted their price target on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Wells Fargo & Company set a $75.00 price target on CRISPR Therapeutics in a research note on Monday, October 13th. Bank of America lifted their price target on CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their price target on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 5th. Ten research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $72.59.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares in the company, valued at $17,262,789.91. The trade was a 16.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel owned 83,402 shares of the company’s stock, valued at $5,554,573.20. This trade represents a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 56,213 shares of company stock valued at $3,810,458 in the last 90 days. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.